ERBB2 and breast cancer: The measurements revealed statistically significant differences between the HER-2+ SK-BR-3 and patients’ HER-2+ breast cancer cells, which were heavily labeled with therapeutics: trastuzumab, anti-HER-2001, anti-HER-2004, anti-HER-2001 × HBsAg, and anti-HER-2004 × HBsAg versus the HER-2− MCF-7 and human breast epithelial cells, which were practically not labeled.